Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Ask Therapept

Plain-English answers grounded in primary literature

Every answer is composed deterministically from verified scientific records, clinical trials, FDA labeling, and analytical lab data. No language model in the loop, zero synthetic hallucinations, and clear distinctions between human trials and animal models.

Popular questions with verified answers:
Medical Boundary:Therapept is an open-access scientific reference and educational catalog, not a clinic or medical provider. Answers are composed deterministically from verified database records, clinical trials, and FDA labeling. We never provide personal diagnoses, medical treatments, or individualized dosing instructions.
Question AnsweredDeterministic Attributed Record

what does tesamorelin do

1

Verified Source-Derived Information

Level 1 · FDA-Approved Drug Product Labeling·Reviewed: 2026-09-24
  • ✓Identity: Synthetic 44-amino-acid GHRH analogue approved by the FDA under the trade name Egrifta.
  • ✓Clinical outcome: Demonstrated 15.2% reduction in visceral adipose tissue (VAT) in Phase 3 clinical trials (Level 1 evidence).
  • ✓Label indication: Indicated strictly for HIV-associated abdominal lipodystrophy; not approved for general anti-aging or cosmetic fat reduction.
Attributed Sources:
2

Educational Explanation & Context

The Plain-English Summary

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates your pituitary gland to release its own natural growth hormone in pulsatile waves, selectively reducing visceral belly fat without shutting down natural hormone feedback.

Technical Mechanism & Details

Tesamorelin binds pituitary GHRH receptors, stimulating cyclic AMP (cAMP) and triggering pulsatile release of endogenous growth hormone. Circulating GH reaches the liver, prompting hepatic IGF-1 synthesis (+81%). This cascade selectively mobilizes deep visceral adipose tissue (-15.2% in Phase 3 trials) while preserving normal somatostatin negative-feedback loops, preventing the supraphysiological hormone spikes common with direct synthetic growth hormone injections.

Tesamorelin is commercially marketed as Egrifta and is approved specifically for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.

Unlike exogenous human growth hormone (hGH), which floods the system and shuts down natural pituitary output, Tesamorelin works upstream through the brain's natural regulatory pathway.

3

Unknown / Not Available & Regulatory Boundaries

Approved exclusively for HIV-associated visceral lipodystrophy. Off-label use for visceral fat reduction in healthy adults has limited long-term controlled trial data.

Explicit Limitations & File Gaps:
  • •Tesamorelin is NOT approved for general weight loss or lifestyle anti-aging in non-HIV populations.

Helpful Follow-Up Questions

Related Guides & References on Therapept

How Ask Therapept Works: Deterministic Transparency

  • •Zero AI Hallucinations: Every answer is synthesized directly from verified database records, published peer-reviewed studies, FDA drug labels, and analytical chemistry testing guides. There is no generative language model fabricating unverified claims.
  • •Source Tier Transparency:Claims follow Therapept’s Level 1–5 evidence hierarchy — official FDA labeling, peer-reviewed research, editorial synthesis, and separated community signals.
  • •Honest Limits: Therapept will not provide personal medical advice, recommend unapproved dosages, or turn forum gossip into facts. When information is unstudied or restricted, Therapept states so clearly.